Van beleggers
voor beleggers
desktop iconMarkt Monitor


  • Geen account? Registreren

Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel PAVmed OTC:PAVM.Q, US70387R1068

  • 0,960 29 jun 2022 22:00
  • -0,002 (-0,23%) Dagrange 0,902 - 0,978
  • 729.829 Gem. (3M) 1,8M

Forum PAVmed geopend

16 Posts
| Omlaag ↓
  1. IEX - Forummoderator 29 december 2020 04:52
    PAVmed Inc. (Nasdaq:PAVM) is an American highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

    Groet Henk

    Van de PAVmed site. Let op deze bewoording: unique and proven business model.
  2. forum rang 8 Leefloon 29 december 2020 09:35

    IEX - Forummoderator schreef op 29 december 2020 04:52:

    Van de PAVmed site. Let op deze bewoording: unique and proven business model.
    Let als belegger dan ook op wat erachter staat, een model "designed to advance products from concept to commercialization". Een aanwijzing voor verlies, en dat lijden ze dan ook. Wat (bijvoorbeeld) medisch uniek en bewezen of interessant is, is niet per se financieel interessant. En ja, een omslag naar winst zou kunnen volgen.
  3. MarkvB 6 januari 2021 15:42
    PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
    Download as PDFJanuary 06, 2021 9:29am EST
    NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a price of $2.24 per share for gross proceeds of approximately $13.4 million in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules.

    The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. The Offering is expected to close on or about January 8, 2021 subject to the satisfaction of customary closing conditions.

    Maxim Group LLC is acting as the sole placement agent in connection with the Offering.

    The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-248709) declared effective by the Securities and Exchange Commission on September 17, 2020. A prospectus supplement relating to the Offering is being filed with the Securities and Exchange Commission. Copies of the prospectus supplement relating to the offering, together with the accompanying base prospectus included in the registration statement, may be obtained from the Securities and Exchange Commission at, or from the Company at One Grand Central Place, Suite 4600, New York, New York 10165, Telephone (212) 949-4319. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    About PAVmed

    PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical device company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmed’s diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health (EsoGuard® Esophageal DNA Test, EsoCheck® Esophageal Cell Collection Device, and EsoCure™ Esophageal Ablation Device with Caldus™ Technology), Minimally Invasive Interventions (CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome), Infusion Therapy (PortIO™ Implantable Intraosseus Vascular Access Device and NextFlo™ Highly Accurate Infusion Platform Technology), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit and follow us on Twitter, Facebook and Instagram.

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, PAVmed’s ability to complete the offering; volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company’s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
  4. forum rang 4 Osho 14 januari 2021 15:50
    Ik zocht een $ONCT forum, maar kwam terecht bij $PAVM

    Ben zelf niet echt van de Bio's maar dit zijn 2 aandelen waar ik toch flink in geinvesteerd heb.
    Een 3e partij waar ik nu 4/5 weken in zit is $DMTK - Testen voor huidkanker vanuit huis realiseren. Is al 3x over de koop.

    $ONCT lijkt vandaag uit te breken. PAVM heeft een 3e private placement in 2 maanden tijd. Die zal nog even duren.

    Ben de laatste tijd aan het overtrade door de SPAC's, dus zoek weer naar wat stabiele aandelen. Lekker conservatief.
  5. forum rang 4 Wil Helmus 18 april 2021 09:27
    Must read Pavmed draadje op twitter:

    Deep Dive on Lucid Diagnostics $PAVM
    - Product Offering
    - $EXAS for esophageal cancer?
    - Market Sizing
    - Go-to-Market Strategy
    - Massive Return Potential (>10x)

    Future $PAVM threads on other segments and risk.

    Have a starter position.
    Please DYODD.
    Let's dig in.
  6. MamiMoMan 6 januari 2022 15:39
    Jammer dat de huidige situatie op de beurs zo hard inhakt op Pavmed. Anders had de bodem er heel anders uit gezien. Momenteel een koopje om in te slaan. Zal zeker terug herstellen dus ik houd alles vast en koop rond de 2 dollar wat stukken bij. Ik verwacht een herstel richting de 8 dollar, maar het zal tijd vragen. Alle begin is moeilijk en Pavmed krijgt momenteel de wind van voren :) komt goed! I'm a believer.

    Wat zijn jullie thoughts?
16 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

PAVmed Meer »

Koers 0,960   Verschil 0,00 (-0,23%)
Laag 0,902   Volume 729.829
Hoog 0,978   Gem. Volume 1.760.528
29 jun 2022 22:00


Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links